| Autor: |
Sethi, K. D., O'Brien, C. F., Hammerstad, J. P., Adler, C. H., Davis, T. L., Taylor, R. L., Sanchez-Ramos, J., Bertoni, J. M., Hauser, R. A. |
| Předmět: |
|
| Zdroj: |
Archives of Neurology; Sep98, Vol. 55 Issue 9, p1211, 6p |
| Abstrakt: |
Objective: To evaluate ropinirole hydrochloride as dopaminergic monotherapy in patients with early Parkinson disease. Design: A 6-month extension of a double-blind, placebo-controlled study. Setting: Ambulatory care at 22 different sites in the United States. Patients: Patients who successfully completed the initial 6-month study could enter the 6-month extension study (ropinirole, n=70; placebo, n=77). Intervention: Use of ropinirole or placebo therapy. Main Outcome Measures: The efficacy variables were the number of patients who successfully completed the 12-month study and did not require supplemental levodopa, the number of patients requiring supplemental levodopa, and the proportion of patients having an insufficient therapeutic response. Results: Significantly fewer ropinirole-treated patients met criteria for insufficient therapeutic response (23 [19.8%] of 116) or required the initiation of levodopa therapy (22 [19%] of 116) compared with placebo-treated patients (60 [48%] of 125 patients for insufficient therapeutic response; 57 [45.6%] of 125 patients for additional levodopa). Significantly more ropinirole-treated patients (51 [44.0%] of 116) successfully completed the 12-month study and did not require supplemental levodopa compared with placebo-treated patients (28 [22.4%] of 125). The incidence of adverse experiences and patient withdrawals was low. Conclusion: Ropinirole was effective and well tolerated as monotherapy for 12 months in patients with early Parkinson disease. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
